Cat. No.: HY-N0385

Gomisin J

3 Cited Publications

Avis client

Based on 3 publication(s) in Google Scholar

Gomisin J is a Schisandra chinensis-derived lignan that can inhibit multiple targets such as eNOS, AMPK (LKB1, CaMKIIβ), fetuin-A, NF-κB, Nrf2/HO-1, and can pass through the blood-brain barrier. Gomisin J increases NO bioavailability by activating eNOS, regulates lipid metabolism by activating the AMPK pathway, inhibits fetuin-A and NF-κB to exert anti-inflammatory effects, and activates Nrf2/HO-1 to enhance antioxidant capacity. Gomisin J has the activities of anti-hypertension, regulating liver lipid metabolism, and reducing cerebral ischemia-reperfusion injury, and can be used for research on hypertension, non-alcoholic fatty liver disease, cerebral ischemia-reperfusion injury, etc.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté: 99.97%
CAS No.: 66280-25-9
Formule: C₂₂H₂₈O₆
Masse moléculaire:388.45

Stockage:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Gomisin J Chemical Structure

CAS No.: 66280-25-9

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (3)
Solvant et solubilité
- In Vitro
- In Vivo
Pureté et documentation
Références
Help & FAQs
Classifications
Bioz

Activité biologique

Description

IC₅₀ & Target^[2]

AMPK

eNOS

Voir tous les produits spécifiques à Isoform NO Synthase :

Voir tous les produits spécifiques à Isoform NF-κB :

Voir tous les produits spécifiques à Isoform CaMK :

Voir tous les produits spécifiques à Isoform AMPK :

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	>100 μM Compound: Gomisin J	Antiproliferative activity against human A549 cells after 72 hrs by SRB assay Antiproliferative activity against human A549 cells after 72 hrs by SRB assay	[PMID: 18063366]
H9	EC₅₀	3.9 μM Compound: 3	Antiviral activity against HIV1 3B in H9 cells after 4 days by p24-antigen ELISA Antiviral activity against HIV1 3B in H9 cells after 4 days by p24-antigen ELISA	[PMID: 17190445]
H9	IC₅₀	23.2 μM Compound: 3	Cytotoxicity against human H9 cells after 4 days Cytotoxicity against human H9 cells after 4 days	[PMID: 17190445]
HCT-15	IC₅₀	>100 μM Compound: Gomisin J	Antiproliferative activity against human HCT15 cells after 72 hrs by SRB assay Antiproliferative activity against human HCT15 cells after 72 hrs by SRB assay	[PMID: 18063366]
HeLa	IC₅₀	>100 μM Compound: 4	Cytotoxicity against human HeLa cells after 72 hrs by MTT assay Cytotoxicity against human HeLa cells after 72 hrs by MTT assay	[PMID: 23237974]
HL-60	IC₅₀	>160.9 μM Compound: 10	Antioxidant activity in human HL60 cells assessed as inhibition of TPA-stimulated hydrogen peroxide induced DCFH-DA oxidation by fluorometric microplate assay Antioxidant activity in human HL60 cells assessed as inhibition of TPA-stimulated hydrogen peroxide induced DCFH-DA oxidation by fluorometric microplate assay	[PMID: 16562834]
HL-60	IC₅₀	54.8 μM Compound: 10	Cytotoxicity against human HL60 cells by XTT assay Cytotoxicity against human HL60 cells by XTT assay	[PMID: 16562834]
K562	IC₅₀	>100 μM Compound: Gomisin J	Antiproliferative activity against human K562 cells after 72 hrs by MTT assay Antiproliferative activity against human K562 cells after 72 hrs by MTT assay	[PMID: 18063366]
Lewis lung carcinoma cell line	IC₅₀	>100 μM Compound: 4	Cytotoxicity against mouse LLC cells after 72 hrs by MTT assay Cytotoxicity against mouse LLC cells after 72 hrs by MTT assay	[PMID: 23237974]
MDA-MB-231	IC₅₀	>100 μM Compound: Gomisin J	Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by SRB assay Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by SRB assay	[PMID: 18063366]
SK-HEP1	IC₅₀	>100 μM Compound: Gomisin J	Antiproliferative activity against human SK-HEP1 cells after 72 hrs by SRB assay Antiproliferative activity against human SK-HEP1 cells after 72 hrs by SRB assay	[PMID: 18063366]
SMMC-7721	IC₅₀	>100 μM Compound: 4	Cytotoxicity against human SMMC7721 cells after 72 hrs by MTT assay Cytotoxicity against human SMMC7721 cells after 72 hrs by MTT assay	[PMID: 23237974]
SNU-638	IC₅₀	>100 μM Compound: Gomisin J	Antiproliferative activity against human SNU638 cells after 72 hrs by SRB assay Antiproliferative activity against human SNU638 cells after 72 hrs by SRB assay	[PMID: 18063366]
T47D	IC₅₀	>100 μM Compound: Gomisin J	Antiproliferative activity against human T47D cells after 72 hrs by SRB assay Antiproliferative activity against human T47D cells after 72 hrs by SRB assay	[PMID: 18063366]
U-87MG ATCC	IC₅₀	>100 μM Compound: 4	Cytotoxicity against human U87 cells after 72 hrs by MTT assay Cytotoxicity against human U87 cells after 72 hrs by MTT assay	[PMID: 23237974]

In Vitro

Gomisin J (10-200 μM; 24 h) has no significant effect on HepG2 cell viability at low doses (≤50 μM)^[2].
Gomisin J (10-40 μM; 24 h) reduces lipid accumulation and TG content induced by oleic acid (HY-N1446) in HepG2 cells, downregulates lipogenic proteins (SREBP-1c, FAS), upregulates lipolytic proteins (PPARα, PGC-1α), activates AMPK and ACC phosphorylation^[2].
Gomisin J (10-40 μM; 24 h) downregulates lipogenic genes (SREBP-1c, FAS, etc.) and inflammatory genes (TNF-α, MCP-1, etc.) in HepG2 cells, upregulates lipolytic genes (PPARα, CPT-1, etc.), and has LKB1-dependent AMPK activation^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

RT-PCR^[2]

Cell Line:

HepG2
Concentration:

10-40 μM
Incubation Time:

1 h pretreatment followed by 24 h Oleic acid (HY-N1446) treatment
Result:

Decreased mRNA levels of SREBP-1c, FAS, ACC, HMGCR, DGAT1, TNF-α, MCP-1, NFKB1, and NFKB2.
Increased mRNA levels of PPARα, PPARδ, PGC-1α, ACOX1, CPT-1, and UCP2.

In Vivo

Gomisin J (1 μg/kg/min and 3 μg/kg/min; osmotic minipump, subcutaneous injection; continuous administration; 14 days) reduces blood pressure, restores plasma NO metabolite levels and vascular NO production, and reduces vascular ROS generation in the Ang II-induced hypertension model of C57BL/6 mice^[1].
Gomisin J (5-80 mg/kg; intraperitoneal injection; single dose before reperfusion; observation until 48 h after reperfusion) dose-dependently reduces neurological function scores, cerebral infarct volume and brain water content, inhibits hippocampal neuronal apoptosis, and reduces inflammation and oxidative stress in the middle cerebral artery occlusion/reperfusion (MCAO/R) model of Wistar rats^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Male Wistar rats (250-300 g) with middle cerebral artery occlusion/reperfusion (MCAO/R) model (occlusion for 2 h followed by reperfusion for 3, 6, 12, 24, or 48 h)^[3]
Dosage:

5, 10, 20, 40, 80 mg/kg
Administration:

Intraperitoneal injection, single administration before reperfusion, observed until 48 h after reperfusion
Result:

Dose-dependently decreased neurological deficit scores, reduced cerebral infarct volume and brain water content, rescued the reduction in hippocampal neuron survival, inhibited apoptosis of ischemic tissues by regulating Bcl-XL, cleaved caspase-3 and Bax, alleviated inflammation by reducing p-p65, COX-2 and NO levels, and enhanced antioxidant capacity by promoting Nrf2 translocation, HO-1 expression, and activities of SOD, GSH-Px as well as GSH level.

Chemical Information

CAS No. 66280-25-9
Appearance Solid
Masse moléculaire 388.45
Formule C₂₂H₂₈O₆
Color White to off-white
SMILES

OC1=C(OC)C(OC)=C(C2=C(OC)C(OC)=C(O)C=C2CC(C)C(C)C3)C3=C1
Structure Classification
- Phenylpropanoids
- Lignans
- Phenols
- Monophenols
Initial Source
Livraison

Room temperature in continental US; may vary elsewhere.
Stockage

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Publications (3)

All

Sort by:

Journal Impact Factor

Animals (Basel)

Molecular Characterization of LKB1 of Triploid Crucian Carp and Its Regulation on Muscle Growth and Quality. [Abstract]

2022 Sep 19;12(18):2474. PMID: 36139343
Biochem Biophys Res Commun

Gomisin J inhibits the glioma progression by inducing apoptosis and reducing HKII-regulated glycolysis. [Abstract]

2020 Aug 13;529(1):15-22. PMID: 32560813
Bioengineered

Gomisin J attenuates cerebral ischemia/reperfusion injury by inducing anti-apoptotic, anti-inflammatory, and antioxidant effects in rats. [Abstract]

2022 Mar;13(3):6908-6918. PMID: 35235758

Solvant et solubilité

In Vitro:

DMSO : 100 mg/mL (257.43 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.5743 mL

12.8717 mL

25.7433 mL

5 mM

0.5149 mL

2.5743 mL

5.1487 mL

10 mM

0.2574 mL

1.2872 mL

2.5743 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (6.44 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (6.44 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (6.44 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (288 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Ye BH, et al. Preventive effect of gomisin J from Schisandra chinensis on angiotensin II-induced hypertension via an increased nitric oxide bioavailability. Hypertens Res. 2015 Mar;38(3):169-77. [Content Brief]

[2]. Kim M, et al. Gomisin J Inhibits Oleic Acid-Induced Hepatic Lipogenesis by Activation of the AMPK-Dependent Pathway and Inhibition of the Hepatokine Fetuin-A in HepG2 Cells. J Agric Food Chem. 2015 Nov 11;63(44):9729-39. [Content Brief]

[3]. Min X, et al. Gomisin J attenuates cerebral ischemia/reperfusion injury by inducing anti-apoptotic, anti-inflammatory, and antioxidant effects in rats. Bioengineered. 2022 Mar;13(3):6908-6918. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.5743 mL	12.8717 mL	25.7433 mL	64.3583 mL
	5 mM	0.5149 mL	2.5743 mL	5.1487 mL	12.8717 mL
	10 mM	0.2574 mL	1.2872 mL	2.5743 mL	6.4358 mL
	15 mM	0.1716 mL	0.8581 mL	1.7162 mL	4.2906 mL
	20 mM	0.1287 mL	0.6436 mL	1.2872 mL	3.2179 mL
	25 mM	0.1030 mL	0.5149 mL	1.0297 mL	2.5743 mL
	30 mM	0.0858 mL	0.4291 mL	0.8581 mL	2.1453 mL
	40 mM	0.0644 mL	0.3218 mL	0.6436 mL	1.6090 mL
	50 mM	0.0515 mL	0.2574 mL	0.5149 mL	1.2872 mL
	60 mM	0.0429 mL	0.2145 mL	0.4291 mL	1.0726 mL
	80 mM	0.0322 mL	0.1609 mL	0.3218 mL	0.8045 mL
	100 mM	0.0257 mL	0.1287 mL	0.2574 mL	0.6436 mL

Keywords

Gomisin J

3 Cited Publications

100 mg Obtenir un devis

Subscribe to the

MedChemExpress

Newsletter

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

Gomisin J

Epigenetics Compound Library

Immunology/Inflammation Compound Library

Neuronal Signaling Compound Library

NF-κB Signaling Compound Library

PI3K/Akt/mTOR Compound Library

Stem Cell Signaling Compound Library

Natural Product Library

Anti-Aging Compound Library

Antioxidant Compound Library

Differentiation Inducing Compound Library

Oxygen Sensing Compound Library

Anti-Cardiovascular Disease Compound Library

Ferroptosis Compound Library

Phenols Library

Glycolysis Compound Library

Pyroptosis Compound Library

Cytoskeleton Compound Library

Traditional Chinese Medicine Active Compound Library

Anti-Breast Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Transcription Factor-Targeted Library

Lipid Metabolism Compound Library

Glucose Metabolism Compound Library

Anti-Liver Cancer Compound Library

Anti-Cancer Natural Product Library

Antidepressant Compound Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Cancer Stem Cells Compound Library

Pain-Related Compound Library

Metabolic Enzyme Compound Library

Membrane Protein-targeted Compound Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Anti-Fibrosis Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

RO5 Drug-like Natural Product Library

Cell Proliferation Compound Library

Lactic Acid Metabolic Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Mass Spectrometry Human Metabolite Library

Mongolian Medicine Compound Library

Natural Product Diversity Scaffold Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Gomisin J

Voir tous les produits spécifiques à Isoform NO Synthase

Voir tous les produits spécifiques à Isoform NF-κB

Voir tous les produits spécifiques à Isoform CaMK

Voir tous les produits spécifiques à Isoform AMPK

Activité biologique

Chemical Information

Publications (3)

Solvant et solubilité

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

Gomisin J Related Classifications

HY-N0385 Related Classifications